SUBSCRIBE
SUBSCRIBE

Propella Therapeutics, Inc.

IN THE PRESS
Deals
Outcome Capital Announces Acquisition of Propella Therapeutics, Portfolio Company of Peterson Companies, by Astellas Pharma
January 4, 2024
 · 
4 min read
Deals
Astellas Completes Acquisition of Propella Therapeutics
December 21, 2023
 · 
3 min read
Deals
Astellas to Acquire Propella Therapeutics
November 15, 2023
 · 
5 min read
Bio NC
Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium
February 14, 2023
 · 
7 min read
Drug Development
Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022
September 8, 2022
 · 
4 min read
Business
Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China
April 7, 2022
 · 
4 min read
Bio NC
Propella Therapeutics Presents Non-Clinical Data on PRL-02 at 2022 ASCO Genitourinary (GU) Cancers Symposium
February 15, 2022
 · 
6 min read
Bio NC
Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
January 3, 2022
 · 
4 min read
Drug Development
Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate CancerNext-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
June 29, 2021
 · 
3 min read
FDA
Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment
May 19, 2021
 · 
3 min read
Load More
JOBS